Enliven Therapeutics, Inc.
NASDAQ:ELVN
17.77 (USD) • At close May 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.317 | 0.297 | 0.622 | 0.099 | 0.097 | 0.033 | 0 | 0 |
| Gross Profit
| 0 | -0.297 | -0.622 | -0.099 | -0.097 | -0.033 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 80.461 | 64.574 | 31.022 | 20.474 | 8.24 | 19.009 | 8.239 | 7.918 |
| General & Administrative Expenses
| 23.776 | 18.955 | 7.769 | 4.288 | 1.078 | 5.107 | 2.438 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | -0.033 | 0 | 0 |
| SG&A
| 23.776 | 18.955 | 7.769 | 4.288 | 1.078 | 5.074 | 2.438 | 0.987 |
| Other Expenses
| 0 | 0 | 0 | 0 | -9.679 | 0 | 0 | 0 |
| Operating Expenses
| 104.554 | 83.529 | 38.791 | 24.762 | 9.318 | 24.083 | 10.677 | 8.905 |
| Operating Income
| -104.554 | -83.529 | -38.791 | -24.762 | -9.318 | -24.116 | -10.677 | -8.905 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 15.298 | 11.945 | 1.129 | 0.022 | -9.648 | 0.653 | -0.66 | 9.126 |
| Income Before Tax
| -89.256 | -71.584 | -37.662 | -24.74 | -18.966 | -23.463 | -11.337 | 0.221 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.232 | 0 | 0.088 | -0.022 | -0.031 | 0.653 | -0.821 | 0.221 |
| Net Income
| -89.024 | -71.584 | -37.75 | -24.718 | -18.935 | -23.463 | -11.337 | 0 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.89 | -2.01 | -6.027 | -3.17 | -14.138 | -5.431 | -2.624 | 0 |
| EPS Diluted
| -1.89 | -2.01 | -6.027 | -3.17 | -14.138 | -5.431 | -2.624 | 0 |
| EBITDA
| -88.475 | -81.932 | -38.576 | -24.647 | -9.273 | -23.43 | -11.337 | 0.221 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |